Proud of the European Cardiology Review Journal …an ever increasing impact factor now 3.2 Well done ! Juan Carlos Kaski and team ecrjournal.com Radcliffe Cardiology

Today is the NHS’s 76th birthday. A battered, bruised, close-to-palliative patient, it’s just been thrown a lifeline. Please save her, Keir Starmer⁩, ⁦Wes Streeting MP⁩ 🙏 Please help us help our patients & rebuild our NHS 💙💙💙

David J. Cohen, MD, MSc David L. Fischman Ron Waksman Michael Savage Mamas A. Mamas Sunil V. Rao Alex Truesdell Poonam Velagapudi MIЯVΛƬ #IC Cardiovascular Business We'll also have BCIS-CHIP3 courtesy of Divaka Perera very soon

Hot off the press for international physicians! 🔥📰 Congratulations to Drs Kevin Cheng, Jonathan Hill and ranil de silva for publishing their new review on the #ShockwaveReducer. In #ICR3Journal, read their great summary on the available evidence and the Reducer’s role in

Huge thanks to all collaborators past, present and future. Good research requires great teams and I’ve been incredibly fortunate to work with some of the very best including Mark Petrie Dr Peter O'Kane Clinical Trials Unit - Global Health Trials Group King's College Hospital Research Lynn Laidlaw (she/her) Yale School of Medicine Guy's & St Thomas' NHS Trust Critical Care Heidi Green, PhD (she/her)

You spent 14 years running the NHS into the ground. Cancer care. Broken. Emergency care. Broken. Mental health. Broken. And a waiting list so long it can be seen from outer space. How do you think this party politicking plays with patients, Tom Tugendhat? The ones I try to care

🎉 We’ve recruited our 250th participant at University Hospitals Dorset NHS Foundation Trust Dr Peter O'Kane Jonathan Hinton and co! Thank you to ALL our collaborators for getting us to this special milestone!🥳

We started this program in 2018 to give early career interventionalists an opportunity to participate in the scientific publishing process. If you're interested in working with a great team please consider applying!

"Intracoronary imaging guidance by IVUS or OCT is recommended for performing PCI on anatomically complex lesions, in particular left main stem, true bifurcations and long lesions. " EHJ2024 OCTOBER Trial Evald Høj Christiansen Gregg W. Stone MD Lene Nyhus Andreasen Ziad Ali Dr Peter O'Kane Omeed Neghabat

Great news with 1A recommendation on imaging in complex lesions. SCAAR is ahead of the curve and has implemented imaging as a quality indicator in PCI. Will help to drive adoption of imaging leading to a meaningful clinical improvement for our patients!

great achievement! those we work with #IC imaging we know how difficult is to get it accepted in daily practice from our colleagues and from our administrators. we finally get it. congrats to those who have worked hard in building the evidence PCRonline 🫀

The historical benefit of treatment with B-blocker after MI has been questioned in our era of modern reperfusion strategies. Interrupting b-blocker after MI in preserved LVEF > 40% is not safer than continuing b-blocker, may result in more hospitalizations. Watch my interview

Not long to go now. We are all set for #BLmT2024. Looking forward to seeing you all. Millbrook Medical Conferences Dr Peter O'Kane Shockwave Medical APR Medtech VP Med Group Medtronic B. Braun Medical Ltd (United Kingdom) Boston Scientific MFT NHS NW Hearts Mamas A. Mamas Elliot Smith Sue Steele Janet Bates Ferrah Choudhary GMEC SCN

ESC guidelines for PCI in severe LV impairment changed from 2a LoE C (should be done in most patients, based on consensus) to 2b LoE B (may be done in selected patients, based on randomised data).#ESCCongress 🙏🏽REVIVED investigators for providing the supporting evidence

Fantastic today that 2 landmark RCTs our centre University Hospitals Dorset NHS Foundation Trust recruited patients for impacted ESC guidelines to direct future care: OCTOBER Trial pushing IC imaging toward 1A REVIVED shifting PCI in ICM down to 2bB Great CI leadership Niels R. Holm & Divaka Perera #researchwin🏆

Ischemia analysis of REVIVED #ESCCongress 💜 approx 20% of LV scarred 30% ischemic on CMR 🏥 very high rates of death or aborted sudden death 📈 amount of ischemia not associated with risk of events 📈 no benefit of PCI whether ischemia extensive or mild/moderate

How do we reconcile STICH and REVIVED? Would CABG offer survival benefit with contemporary medical therapy? ➡️ Answers at late breaking science session #ESCCongress2024 this morning! Results from the first pooled individual patient level analyses from these two RCTs

Fascinating talks using pooled data from REVIVED (R) + STICH (S) ➡️ R patients had higher baseline surgical risk ➡️ No difference in tx effect in either trial by surgical risk ➡️ S-OMT arm had worse outcomes than R-OMT ➡️ R-OMT arm had better outcomes than S-CABG! #ESCCongress

Matt Daniels MD PhD Matt Ryan Guillaume Marquis-Gravel Divaka Perera Mark Petrie REVIVED Eric J Velazquez Aaysha Cader European Society of Cardiology Dr Peter O'Kane EHJ Editor-in-Chief Similar BB and ACEi usage in both Plus small amount of entresto use in R, but minimal SGLT2 Over 50% had a device in REVIVED by trial end ahajournals.org/doi/10.1161/CI…

MIЯVΛƬ #IC European Society of Cardiology PCRonline 🫀 Niels R. Holm Salvatore Brugaletta Robert W. Yeh MD Sunil V. Rao David J. Cohen, MD, MSc Erik Rafflenbeul Valeria Paradies Khaled AlShaibi Rodrigo Bagur 🇦🇷🇨🇦 Oscar Mendiz It would also be appropriate to conclude that DCBs don’t have a class effect. We learnt from prev failures that not all DES or DCBs are created equally. What preclinical or angiographic data do we have on this balloon? Are these data really applicable to all DCBs? I think not!